Raleigh firm's 'Female Viagra' safe and effective for breast cancer patients, study finds.
An ongoing clinical trial of Sprout Pharmaceuticals' "female Viagra" drug, Addyi, for the treatment of low sexual desire in women has found that it can be used safely and effectively in women with breast cancer. The study, conducted through Memorial Sloan Kettering Cancer Center, plans to enroll 43 women and has shown statistically significant improvement in libido and other areas. Sprout Pharmaceuticals was approved by the FDA in 2015 but has yet to prove to be the financial boon expected, leading to the $1 billion sale of the company in 2015.